Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Ulnar sensory-motor amplitude ratio: a new tool to differentiate ganglionopathy from polyneuropathy Razão de amplitude sensitivo-motora ulnar: novo parâmetro para diferenciar ganglionopatia de ...

In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.

Timberlake said the diagnosis helped explain the persistent fatigue, nerve pain, and unexplained illness he had been ...